Managing gBRCA-Positive Metastatic Breast Cancer

Introduction

When Would You Initiate BRCA Mutation Testing?

BRCA Mutation Prevalence: Higher Risk Groups Appropriate for BRCA Testing

Prevalence of Germline BRCA1/2 Mutations

BRCA1/2 Testing Current Guidelines

Issues in BRCA Mutation Testing: When and Why?

Issues in BRCA Mutation Testing: When and Why? (cont)

Case Discussion: A Patient With BRCA+ MBC Who Did Not Receive Prior Chemotherapy

Clinical Case - Ms S.

Clinical Case - Ms S. (cont)

Clinical Case - Ms S. (cont)

Case Discussion

Phase 3 OlympiAD Trial: PFS

Phase 3 EMBRACA Study: PFS

OlympiAD Overall Survival and Subgroup Analysis

Phase 3 PARP Inhibitor Trials: Safety and QoL

Olaparib and Talazoparib Safety Data: AEs of Any Grade

Olaparib and Talazoparib QoL

What Is the Role of Platinum in the Treatment of BRCA1/2 Carriers?

Is There a Role for PARP Inhibitors in Patients With Somatic BRCA Mutations?

What Is the Role of PARP Inhibitors in the Adjuvant Setting?

Talazoparib Neoadjuvant

Concluding Remarks

Abbreviations

Abbreviations (cont)